Nebenwirkungen · Mavenclad
MAVENCLAD 10 mg tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-136717 · Präparat HOS-097904
In clinical studies of patients treated with a cumulative dose of 3.5 mg/kg oral cladribine, hypersensitivity events were observed more frequently in cladribine-treated patients (11.8%) compared to patients who received placebo (8.4%). Serious hypersensitivity events were observed in 0.3% of cladribine-treated patients and in no patients who received placebo. Hypersensitivity events led to treatment discontinuation in 0.4% of cladribine-treated patients and in 0.3% patients who received placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T15:14:00Z · SHA-256 a722a20cdc802548a0143470c5746ad3af0e38cfea6037582fc25a1fbf447edf · Passage 1637755751e04069aeaaee0529077393cf3f5d34c67d1fb82ac304938a11f136 · Zeichen 2983–3483 im Abschnitt